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Current guidelines by the National Comprehensive Cancer 
Network recommend that, in addition to routine computed 
tomography (CT) imaging, bone imaging and brain magnetic 
resonance imaging (MRI) should be obtained when clinically 
indicated. In this issue of the Journal of Kidney Cancer and 
VHL, a systematic literature review of clinical trials of met-
astatic renal cell carcinoma (mRCC) patients evaluates the 
incidence of osseous, lymph node, and lung metastases  (1). 
In particular, the analysis by Lin et al focuses on the changes 
in incidence over time. The study finds that the incidence of 
bone, lymph node, and lung metastases has increased over 
time. This increase is significant in osseous metastases specif-
ically. These results lead to two provocative questions. First, 
why have osseous metastases increased in incidence over 
time? Second, does this finding warrant a more aggressive 
and uniform approach to imaging to identify osseous metas-
tases sooner?
The cause of an increased incidence of osseous metastases 
overtime may be multifactorial. For example, an increased 
incidence of kidney cancer has been appreciated for some 
time and is partly because of advances in and increased use 
of imaging (2). This may, in part, explain the increased inci-
dence of osseous metastases over time. One limitation of 
the current analysis is that the authors could not delve into 
granular details of imaging requirements in the compiled 
trials and their change over time. Increased incorporation of 
bone imaging into trial protocols may have resulted in higher 
detection of osseous metastases.
However, just as the increased incidence of kidney can-
cer likely cannot be explained by increased use of imaging 
alone, similarly, the natural history of kidney cancer must 
be considered when examining this increased incidence of 
bone metastases. In particular, the evolving treatment para-
digms of mRCC have led to dramatic extensions in survival. 
For example, consider that the SWOG-8949 trial of patients 
treated with interferon alfa-2b and cytoreductive nephrec-
tomy demonstrated a median overall survival (OS) of 11.1 
months (3). In contrast, even with extended follow-up from 
the more recent KEYNOTE-426 study, the median OS of 
patients treated with the combination of pembrolizumab 
plus axitinib has still not been reached, whereas the median 
OS of patients treated with sunitinib was 35.7 months (4). 
Thus, an increased incidence of bone metastases may be a 
result of extended longevity leading to development of addi-
tional metastatic sites. Interestingly, the current analysis did 
evaluate differences in the incidence of bone metastases in 
the first-line setting (28%) versus in patients being treated 
in the second-line setting or beyond (29%). So, this study 
has not demonstrated that osseous metastases are late-stage 
sequelae of mRCC.
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Another limitation of the literature review is that the out-
comes were not evaluated concerning osseous metastases. 
Some studies have suggested that patients with bone metas-
tases have worse results. An analysis of the International 
Metastatic Renal Cell Carcinoma Database Consortium 
during the era of vascular endothelial growth factor tyro-
sine kinase inhibitor (VEGF-TKI) therapy demonstrated 
a median survival of 14.9 months for patients with bone 
metastases, compared with 25.1 months for those without 
bone metastases (5).
Demonstration of an increased incidence of bone metas-
tases over time is not independently a justification for the 
adoption of routine bone imaging in all patients with mRCC. 
When determining whether a test should be routinely and 
uniformly utilized, the application of its results must also 
be considered. In the case of osseous metastases, one must 
consider the benefits of early intervention in asymptomatic 
patients or if  therapies are specifically beneficial to patients 
with osseous metastases. Bone-targeted therapies like zole-
dronic acid and denosumab have shown demonstrated ben-
efits in delaying skeletal-related events in mRCC patients in 
small studies or subset analyses. Their gain has not been sig-
nificant in the current era since the use of VEGF-TKIs (6). 
Though bone-targeted therapies are still routinely used in 
patients with mRCC, their use alone is not currently a justifi-
cation for routine bone imaging.
Whether mRCC patients with osseous metastases may 
benefit from specific therapies remains an area of interest. 
Cabozantinib could potentially alter the bone microenviron-
ment, and as a result, been studied in patients with mRCC 
who have osseous metastases. The Phase III METEOR study 
evaluated and demonstrated a clinical benefit of cabozan-
tinib compared with everolimus in patients with refractory 
mRCC (7, 8). The protocol required routine bone imaging 
before enrollment and during treatment. Subgroup anal-
ysis was performed on this study of patients with osseous 
metastases at baseline before treatment, demonstrated supe-
rior progression free survival, OS, and objective response 
rate in patients treated with cabozantinib. As the land-
scape of mRCC continues to evolve, findings such as these 
become pivotal in determining the appropriate sequencing 
of therapies in the second line and beyond setting. A cur-
rent cooperative group study (RadiCaL) is evaluating the 
combination of cabozantinib with or without Radium-223 
dichloride in mRCC patients who have osseous metastases 
(NCT04071223). In the first-line setting, insufficient data are 
comparing current standard of care treatments that combine 
immune checkpoint inhibitors with VEGF TKIs to deter-
mine if  a cabozantinib- containing combination is beneficial 
in treatment-naïve mRCC patients with osseous metastases.
While it may be premature to incorporate routine bone 
imaging in the treatment of mRCC patients based on the 
results of this systematic literature review, including rou-
tine bone imaging in clinical trials may become increasingly 
important for enhanced determination of sequencing or 
choice of therapies. Studies designed to evaluate patients 
with bone metastases specifically may allow for data that 
may justify the use of routine bone imaging in the future.
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